Skip to content

OS Therapies OSTX Weighted Average Exercise Price of Outstanding Options

Weighted Average Exercise Price of Outstanding Options at other companies

CTO
Citius Oncology, Inc.CTOR
$1.830.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's weighted average exercise price of outstanding options.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's weighted average exercise price of outstanding options?
OS Therapies (OSTX) reported weighted average exercise price of outstanding options of $1.74 in Q1 2026.
How has OS Therapies's weighted average exercise price of outstanding options changed year-over-year?
OS Therapies's weighted average exercise price of outstanding options decreased by 6.5% year-over-year, from $1.86 to $1.74.
What does weighted average exercise price of outstanding options mean?
This metric calculates the average price at which holders of outstanding stock options can purchase company shares. It provides context on the 'in-the-money' status of employee compensation packages. When compared to the current market price, it helps assess the alignment between employee incentives and shareholder value.